News | March 02, 2026
Blue Jet Healthcare breaks ground on Rs. 2,300 crore pharma plant in Andhra Pradesh
The facility is expected to become operational by FY2028-29
The facility is expected to become operational by FY2028-29
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
The EIR was issued following an inspection of the facility from November 10 to November 21, 2025
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Subscribe To Our Newsletter & Stay Updated
